NAPSRx

Chimerix, Inc. (Nasdaq:CMRX), is a biopharmaceutical company focused on developing and commercializing novel, oral antivirals in areas of high unmet medical need.

Actavis will acquire Durata’s novel antibiotic DALVANCE - the first and only IV antibiotic approved for the treatment of ABSSSI.

Novartis and Bristol-Myers Squibb will join forces on a clinical collaboration which involves evaluating the safety, tolerability and preliminary efficacy of Zykadia(TM), INC280 and EGF816 in combination with Bristol-Myers Squibb's investigational...

In an effort to boost research and development for therapies and products to treat rare diseases, the U.S.

With the worst Ebola outbreak in history, the virus continues to spread and now there's a confirmed case in the United States. It’s no surprise the experimental ZMapp cocktail has been at the center of discussion as the number one treatment option.

Johnson & Johnson (NYSE: JNJ) joins the list of major pharmaceutical giants acquiring smaller biotech/biopharma firms encompassing a growing trend of big pharma’s initiative to further research and development of specific drugs to treat rare...

Daiichi Sankyo Company Ltd and Ambit Biosciences, a U.S.  based biopharmaceutical company, have announced their plans to enter into a definitive merger agreement.

The U.S Food and Drug Administration (FDA) has approved the inhalation mist version of Boehringer Ingelheim’s Spiriva® Respimat®  (tiotropium bromide) to treat bronchospasm associated with chronic obstructive pulmonary disease (COPD), including...

Acorda Therapeutics announced on September 24, 2014, their plans to acquire Civitas Therapeutics, a privately-held biopharmaceutical company, for $525 million in cash.

The U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) administered as a oral, selective inhibitor of phosphodiesterase 4 (PDE40 to treat  patients with with moderate to severe plaque psoriasis for whom phototherapy or...